High Expression of RhoBTB3 Predicts Favorable Chemothrapy Outcomes in non-M3 Acute Myeloid Leukemia

作者：Shuanghui Yang, Wei Liu, Jie Peng, Yajing Xu, Yanfeng Liu, Yan Li, Minyuan Peng, Zhao Ouyang, Cong Chen, Enyi Liu · 发表于：Journal of Cancer · 年份：2021 · DOI：10.7150/jca.50472 · 被引用次数：7 · 研究领域：Acute Myeloid Leukemia Research、Cancer, Hypoxia, and Metabolism、Myeloproliferative Neoplasms: Diagnosis and Treatment

The expression patterns and prognostic significance of the Rho family GTPases in acute myeloid leukemia have not been systematically studied yet. Methods: In our study, we analyzed the expression patterns of 21 Rho family GTPases gene members in AML patients based on GEPIA database. 10 gene members with significant differential expression in AML tissue and healthy tissue were selected for subsequent research. Survival curve analysis in TCGA and GEO dataset preliminary showed that RhoBTB3 is related with the prognosis of non-M3 AML patients. The differential expression of RhoBTB3 on AML bone marrow and normal bone marrow was verified by RT-qPCR. We performed Kaplan-Meier survival analysis and Multivariate Cox analysis to assess the prognostic value of RhoBTB3 in non-M3 AML patients with different treatment regimens. Gene functional enrichment analysis of RhoBTB3 was performed using GO, KEGG and PPI network.